Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Change in Receivables: 2015-2025

Historic Change in Receivables for Sunshine Biopharma (SBFM) over the last 7 years, with Sep 2025 value amounting to $649,850.

  • Sunshine Biopharma's Change in Receivables rose 165.84% to $649,850 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 34.64%. This contributed to the annual value of $2.3 million for FY2024, which is 293.54% up from last year.
  • Sunshine Biopharma's Change in Receivables amounted to $649,850 in Q3 2025, which was up 1,088.95% from -$65,711 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Change in Receivables registered a high of $1.8 million during Q2 2024, and its lowest value of -$986,986 during Q3 2024.
  • Its 3-year average for Change in Receivables is $280,891, with a median of $191,051 in 2023.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 3,166,200.00% in 2023, then slumped by 1,658.68% in 2024.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Change in Receivables stood at $6,669 in 2021, then skyrocketed by 7,881.14% to $532,262 in 2022, then declined by 10.63% to $475,659 in 2023, then soared by 113.81% to $1.0 million in 2024, then skyrocketed by 165.84% to $649,850 in 2025.
  • Its Change in Receivables stands at $649,850 for Q3 2025, versus -$65,711 for Q2 2025 and -$426,673 for Q1 2025.